GPX2 promotes EMT and metastasis in non‐small cell lung cancer by activating PI3K/AKT/mTOR/Snail signaling axis

• DOI: 10.1096/fba.2022-00045
• Publication Date: 2023-03-06T07:24:09Z
• Authors: Fang Peng; Qiushi Xu; Xiaomeng Jing; Xinming Chi; Zheming Zhang; Xiangpeng Meng; Xinyuan Liu; Jiao Yan; Xuefeng Liu; Shujuan Shao
• Keywords: diagnosis; QH301-705.5; EMT; metastasis; Biology (General); NSCLC; Research Articles; 3. Good health; GPX2; IHC

AbstractLung cancer, with non‐small cell lung cancer (NSCLC) being the main subtype, is the leading cause of cancer death worldwide, which is mainly due to the cancer metastasis. Glutathione peroxidase 2 (GPX2), an antioxidant enzyme, is involved in tumor progression and metastasis. Nevertheless, the role of GPX2 in NSCLC metastasis has not been clarified. In this study, we found that GPX2 expression was elevated in NSCLC tissues and high GPX2 expression was correlated with poor prognosis in patients with NSCLC. In addtion, GPX2 expression was related to the patient's clinicopathological features, including lymph node metastasis, tumor size, and TNM stage. Overexpression of GPX2 promoted epithelial–mesenchymal transition (EMT), migration, and invasion of NSCLC cells in vitro. Knockdown of GPX2 showed the opposite effects in vitro and inhibited the metastasis of NSCLC cells in nude mice. Furthermore, GPX2 reduced reactive oxygen species (ROS) accumulation and activated the PI3K/AKT/mTOR/Snail signaling axis. Therefore, our results indicate that GPX2 promotes EMT and metastasis of NSCLC cells by activating the PI3K/AKT/mTOR/Snail signaling axis via the removal of ROS. GPX2 may be an effective diagnostic and prognostic biomarker for NSCLC.